MedTrace Logo

Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery

NCT04542759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-09-09

No results posted yet for this study

Summary

Describe the efficacy of the use of topical besifloxacin in reducing the conjunctival microbiota as a prophylactic measure in patients scheduled for cataract surgery.

Conditions

  • Microbial Disease
  • Cataract Senile

Interventions

DRUG

Besifloxacin Ophthalmic

Prophylaxis for endophthalmitis

DRUG

Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution

Placebo

Sponsors & Collaborators

  • Instituto de Oftalmología Fundación Conde de Valenciana

    lead OTHER

Principal Investigators

  • Eduardo Chavez-Mondragon, MD · Instutute of Ophthalmology "Conde de Valenciana"

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-04-30
Completion
2017-04-30
FDA Drug
Yes

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542759 on ClinicalTrials.gov